4D pharma PLC (LBPS)

July 19, 2022 - LBPS delisted
0.00
0.00 (0.00%)
No quote available
Market Cap 37.19M
Revenue (ttm) 718,000
Net Income (ttm) -31.94M
Shares Out 169.52M
EPS (ttm) -1.50
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Open n/a
Previous Close n/a
Day's Range n/a
52-Week Range n/a
Beta 3.27
Analysts Buy
Price Target 7.52 (+355.8%)
Earnings Date n/a

About LBPS

4D pharma plc, together with its subsidiaries, develops live biotherapeutic products (LBPs) in the United Kingdom. The company develops therapeutic candidates, including MRx0518 for the treatment of cancer and immune-oncology diseases; MRx-4DP0004 for the treatment of asthma; MRx0029 and MRx0005 the treatment of central nervous system disorders; Blautix for irritable bowel syndrome; and Thetanix for pediatric crohn's disease. It also develops products candidates, such as MRx1299 for solid tumors, MRx0006 for rheumatoid arthritis, and MRx0002 fo... [Read more]

Industry Biotechnology
Founded 2014
CEO Duncan Peyton
Employees 106
Stock Exchange NASDAQ
Ticker Symbol LBPS
Full Company Profile

Financial Performance

In 2021, 4D pharma's revenue was $718,000, an increase of 4.06% compared to the previous year's $690,000. Losses were -$31.94 million, 4.73% more than in 2020.

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for LBPS stock is "Buy." The 12-month stock price forecast is 7.52, which is an increase of 355.76% from the latest price.

Price Target
$7.52
(355.76% upside)
Analyst Consensus: Buy
Stock Forecasts

News

4D pharma plc (“4D pharma”) Receives Notice of Delisting From Nasdaq

LEEDS, England--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the ...

5 months ago - Business Wire

Update on Suspension of Trading

LEEDS, England--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD, Nasdaq: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the ...

5 months ago - Business Wire

4D pharma Presents Trial in Progress Poster on Study of MRx0518 in Combination with BAVENCIO® in Patients with Unrese...

LEEDS, England--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the ...

6 months ago - Business Wire

4D pharma to Present at the H.C. Wainwright Global Investment Conference

LEEDS, UK,--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the micr...

6 months ago - Business Wire

4D pharma Presents Late Breaking Abstract from Phase I/II Trial of MRx-4DP0004 for the Treatment of Asthma at the Ame...

LEEDS, England--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the ...

6 months ago - Business Wire

4D pharma Reports Full Year 2021 Financial Results, Operational Highlights, and Guidance for Key Milestones in 2022

LEEDS, England--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the ...

8 months ago - Business Wire

4D Pharma Shares Soar On MRx0518/Keytruda Combo Trial Data In Renal Cell Carcinoma

4D pharma plc (NASDAQ: LBPS) has announced interim results from Phase 1/2 study evaluating the combination of MRx0518 and Merck & Co Inc's (NYSE: MRK) Keytruda (pembrolizumab) for renal cell carcinoma (...

8 months ago - Benzinga

4D pharma Announces Positive Interim Results from the Phase I/II Study of the Combination of MRx0518 and KEYTRUDA® (p...

LEEDS, England--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the ...

8 months ago - Business Wire

4D pharma to Participate at the Chardan Metagenomics and Microbiome Medicines Summit

LEEDS, England--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the ...

9 months ago - Business Wire

4D Pharma To Test Its Single-Strain Live Biotherapeutics In Parkinson's Disease

The FDA has signed off 4D pharma plc's (NASDAQ: LBPS) investigational new drug (IND) applications for two Live Biotherapeutics (LBPs), MRx0005 and MRx0029, for Parkinson's disease.  The Company expects ...

9 months ago - Benzinga

4D pharma Announces FDA Clearance of IND Application for Live Biotherapeutics MRx0005 and MRx0029 for the Treatment o...

LEEDS, England--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the ...

9 months ago - Business Wire

4D Pharma's Asthma Candidate Shows Positive Trends In Multiple Secondary Endpoints Of Efficacy

As previously announced, Part A met the primary endpoint, and the safety profile of MRx-4DP0004 was comparable to placebo.

10 months ago - Benzinga

4D pharma Announces Additional Positive Data From Part A of the Phase I/II Trial Of MRx-4DP0004 For the Treatment of ...

LEEDS, England--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the ...

10 months ago - Business Wire

4D pharma to Host Virtual KOL Event Discussing Asthma Treatment Landscape and Review of Positive Topline Results from...

LEEDS, England--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the ...

10 months ago - Business Wire

4D pharma to Present at the H.C. Wainwright BioConnect Conference

LEEDS, England--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the ...

10 months ago - Business Wire

4D pharma appoints John Doyle as Chief Financial Officer

LEEDS, England--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the ...

11 months ago - Business Wire

4D Pharma Announces Positive Topline Results From Part a of Phase I/II Trial of MRx-4DP0004 for the Treatment of Asthma

LEEDS, England--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the ...

11 months ago - Business Wire

4D pharma Presents Microbiome Analyses from Phase II Clinical Trial of Blautix® for IBS-C and IBS-D at Gastro 2021

LEEDS, England--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the ...

11 months ago - Business Wire

4D pharma to Participate in Jefferies London Healthcare Conference

LEEDS, England--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the ...

1 year ago - Business Wire

4D pharma to Participate in Jefferies Virtual Next Generation IBD Therapeutics Summit

LEEDS, England--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD, NASDAQ, LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the ...

1 year ago - Business Wire

4D pharma Presents Two Clinical Posters for Live Biotherapeutic MRx0518 at the European Society for Medical Oncology ...

LEEDS, England--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the ...

1 year ago - Business Wire

4D pharma to Participate in Upcoming Virtual Investor Conferences in September

LEEDS, England--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the ...

1 year ago - Business Wire

4D pharma Announces Two Presentations at European Society for Medical Oncology (ESMO) Congress 2021

LEEDS, England--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the ...

1 year ago - Business Wire

4D pharma Announces $30 Million Credit Facility with Oxford Finance

LEEDS, England--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the ...

1 year ago - Business Wire

4D pharma Announces Passing of Chief Financial Officer John Beck

LEEDS, England--(BUSINESS WIRE)--4D pharma plc (AIM: DDDD, NASDAQ, LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the ...

1 year ago - Business Wire